# US 2024/0174681 A1 · Salt and crystalline forms of fgfr4 inhibitor and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0174681 A1
- Document ID: US20240174681A1
- Status: Published application
- Kind: A1
- Application number: 17/907,117
- Filed: 2021-03-26
- Published: 2024-05-30
- Earliest claimed: 2020-03-27
- Assignees: Betta Pharmaceuticals Co., Ltd.
- Applicants: Betta Pharmaceuticals Co., Ltd
- Inventors: Jinheng GAO; Xiaofeng XU; Liang CHEN; Zhongxin SUN; Yun ZHANG; Xiangyong LIU; Lieming DING; Jiabing WANG
- Web page: https://patentgrep.com/patent/US20240174681A1

## CPC

- C07D 487/14: Ortho-condensed systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07C 55/14: Adipic acid
- C07C 59/255: Tartaric acid
- C07D 471/14: Ortho-condensed systems
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention relates to a crystalline form and/or maleate, phosphate, L-tartrate, and adipate of the compound represented by the structural formula I, and various crystalline forms of various salt forms, and preparation methods and applications thereof.

## Claims

### Claim 1

A crystal form, a salt form and a crystal form of the salt form of a compound represented by Formula I

### Claim 2 (depends on 1)

The crystal form, the salt form and the crystal form of the salt form according to claim 1, wherein the salt form is selected from a maleate, a phosphate, an L-tartrate or an adipate.

### Claim 3 (depends on 1)

The crystal form, the salt form and the crystal form of the salt form according to claim 1, wherein the salt form is a phosphate whose structure is represented by Formula II:

### Claim 4 (depends on 3)

The crystal form, the salt form and the crystal form of the salt form according to claim 3, wherein the phosphate is a phosphate crystal form 1, and an X-ray powder diffraction pattern of the phosphate crystal form 1 has characteristic peaks at diffraction angles 2θ of 4.9°±0.2°, 10.7°±0.2°, 16.8°±0.2° and 21.3°±0.2°;
Preferably the X-ray powder diffraction pattern of the phosphate crystal form 1 has characteristic peaks at diffraction angles 2θ of 4.9°±0.2°, 8.3°±0.2°, 10.7°±0.2°, 11.6°±0.2°, 12.8±0.2°, 16.8°±0.2° and 21.3°±0.2° ; and
the X-ray powder diffraction pattern of the phosphate crystal form 1 has characteristic peaks at diffraction angles 2θ of 4.9°±0.2°, 8.3°±0.2°, 10.7°±0.2°, 11.6°±0.2°, 12.8±0.2°, 16.8°±0.2°, 20.1°±0.2°, 21.3°±0.2° and 28.5°±0.2°.

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7 (depends on 4)

The crystal form, the salt form and the crystal form of the salt form according to claim 4, wherein the phosphate crystal form 1 has an X-ray powder diffraction pattern substantially as shown in FIG. 9 or FIG. 10.

### Claim 8 (depends on 1)

The crystal form, the salt form and the crystal form of the salt form according to claim 1, wherein the salt form is a maleate.

### Claim 9 (depends on 8)

The crystal form, the salt form and the crystal form of the salt form according to claim 8, wherein the maleate is a maleate crystal form 1, and an X-ray powder diffraction pattern of the maleate crystal form 1 has characteristic peaks at diffraction angles 2θ of 3.7°±0.2°, 9.9°±0.2°, 16.2°±0.2° and 11.0°±0.2;
Preferably the X-ray powder diffraction pattern of the maleate crystal form 1 has characteristic peaks at diffraction angles 2θ of 3.7°±0.2°, 9.9°±0.2°, 11.0°±0.2°, 13.4°±0.2°, 16.2±0.2°, 17.2°±0.2° and 20.6°±0.2° ; and
Preferably the X-ray powder diffraction pattern the maleate crystal form 1 has characteristic peaks at diffraction angles 2θ of 3.7°±0.2°, 9.9°±0.2°, 11.0°±0.2°, 13.4°±0.2°, 16.2°±0.2°, 17.2°±0.2°, 18.7°±0.2°, 19.4°±0.2°, 20.6°±0.2°, 22.6°±0.2° and 24.4°±0.2°.

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12 (depends on 9)

The crystal form, the salt form and the crystal form of the salt form according to of claim 9, wherein the maleate crystal form 1 has an X-ray powder diffraction pattern substantially as shown in FIG. 4.

### Claim 13 (depends on 1)

The crystal form, the salt form and the crystal form of the salt form according to claim 1, wherein the crystal form is a crystal form A of the compound represented by Formula I, and an X-ray powder diffraction pattern of the crystal form A has characteristic peaks at diffraction angles 207.5°±0.2°, 10.7°±0.2°, 11.3°±0.2° and 15.1°±0.2°;
preferably the X-ray powder diffraction pattern of the crystal form A has characteristic peaks at diffraction angles 2θ of 7.5°±0.2°, 10.7°±0.2°, 11.3°±0.2°, 13.1°±0.2°, 15.1°±0.2°, 20.9°±0.2° and 25.2°±0.2° ; and
preferably the X-ray powder diffraction pattern of the crystal form A has characteristic peaks at diffraction angles 2θ of 7.5°±0.2°, 10.7°±0.2°, 11.3°±0.2°, 13.1°±0.2°, 15.1°±0.2°, 20.9°±0.2°, 21.6°±0.2°, 22.8±0.2°, 23.5°±0.2°, 25.2°±0.2° and 30.2±0.2°.

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16 (depends on 13)

The crystal form, the salt form and the crystal form of the salt form according to claim 13, wherein the crystal form A has an X-ray powder diffraction pattern substantially as shown in FIG. 1.

### Claim 17 (depends on 1)

The crystal form, the salt form and the crystal form of the salt form according to claim 1, wherein the salt form is an L-tartrate, the L-tartrate is an L-tartrate crystal form 1, and an X-ray powder diffraction pattern of the L-tartrate crystal form 1 has characteristic peaks at diffraction angles 2θ of 5.4°±0.2°, 17.6°±0.2°, 19.7°±0.2° and 20.7°±0.2°;
Preferably the X-ray powder diffraction pattern of the L-tartrate crystal form 1 has characteristic peaks at diffraction angles 2θ of 5.4°±0.2°, 12.9°±0.2°, 16.5°±0.2°, 17.6°±0.2°, 19.7±0.2° and 20.7°±0.2°; and
Preferably the X-ray powder diffraction pattern of the L-tartrate crystal form 1 has characteristic peaks at diffraction angles 2θ of 5.4°±0.2°, 12.9°±0.2°, 16.5°±0.2°, 17.6°±0.2°, 19.7±0.2°, 20.7°±0.2°, 22.2°±0.2° and 26.4°±0.2°.

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20 (depends on 17)

The crystal form, the salt form and the crystal form of the salt form according to claim 17, wherein the L-tartrate crystal form 1 has an X-ray powder diffraction substantially as shown in FIG. 13.

### Claim 21 (depends on 1)

The crystal form, the salt form and the crystal form of the salt form according to claim 1, wherein the salt form is an adipate, the adipate is an adipate crystal form 1, and an X-ray powder diffraction pattern of the adipate crystal form 1 has characteristic peaks at diffraction angles 2θ of 5.8°±0.2°, 8.4°±0.2°, 12.3°±0.2° and 22.9°±0.2°;
Preferably the X-ray powder diffraction pattern of the adipate crystal form 1 has characteristic peaks at diffraction angles 2θ of 5.8°±0.2°, 8.4°±0.2°, 10.0°±0.2°, 10.4°±0.2°, 12.3±0.2°, 17.5°±0.2° and 22.9°±0.2°; and
Preferably the X-ray powder diffraction pattern of the adipate crystal form 1 has characteristic peaks at diffraction angles 2θ of 5.8°±0.2°, 8.4°±0.2°, 10.0°±0.2°, 10.4°±0.2°, 12.3±0.2°, 17.5°±0.2°, 22.9°±0.2°, 25.4°±0.2° and 25.9°±0.2°.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24 (depends on 21)

The crystal form, the salt form and the crystal form of the salt form according to claim 21, wherein the adipate crystal form 1 has an X-ray powder diffraction pattern substantially as shown in FIG. 16.

### Claim 25 (depends on 1)

A pharmaceutical composition, comprising a therapeutically effective amount of the crystal form,. the salt form and the crystal form of the salt form according to claim 1 and a pharmaceutically acceptable excipient, adjuvant and/or carrier.

### Claim at position 26

26-30. (canceled)

### Claim 31 (depends on 25)

A method for treatment, prophylaxis, and delaying or preventing the occurrence or progression of cancer or cancer metastasis by administering a therapeutically effective amount of the composition according to claim 25 to a subject in need.

### Claim 32 (depends on 1)

A method for treating an FGFR4-mediated disease by administering a therapeutically effective amount of the crystal form, the salt form and the crystal form of the salt form according to claim 1 to a subject in need.

### Claim 33 (depends on 32)

The method of claim 32, wherein the FGFR4-mediated disease is cancer.

### Claim 34 (depends on 33)

The method of claim 33, wherein the cancer is selected from breast cancer, multiple myeloma, bladder cancer, endometrial cancer, gastric cancer, cervical cancer, rhabdomyosarcoma, non-small-cell lung carcinoma, small-cell lung carcinoma, pleomorphic lung cancer, ovarian cancer, esophageal carcinoma, melanoma, colorectal carcinoma, hepatocellular carcinoma, head and neck neoplasm, intracranial tumor, hepatocholangiocarcinoma, myelodysplastic syndrome, glioblastoma, prostate cancer, thyroid cancer, Schwann cell tumor, squamous-cell lung carcinoma, lichenoid keratosis, synoviosarcoma, skin cancer, pancreatic cancer, testicular cancer and liposarcoma.
